Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
Sponsorjohn eisenbrey
About this trial
This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.
Eligibility criteria
Qualifiers
Previously received cryotherapy or microwave therapy of RCC
Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy
Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study
Be at least 18 years of age
Disqualifiers
Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
Patients with known sensitivities to the components of Lumason
Trial design
Treatments tested in this trial
- Sulfur Hexafluoride Lipid Microspheres
- Contrast-Enhanced Ultrasound
- Computed Tomography
- Magnetic Resonance Imaging
- Electronic Health Record Review
Treatment groups
210 Participants
are divided into 1 treatment groupSponsors and collaborators
john eisenbrey
Lead sponsor
Thomas Jefferson University
Sponsor institution
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov